Literature DB >> 12018671

Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water.

E Sakhnini1, A Weissmann, I Oren.   

Abstract

Soft tissue infection caused by Stenotrophomonas maltophilia is uncommon, but nosocomial infections had been reported. We describe herein 2 young female patients, with severe neutropenia, on broad spectrum antimicrobial agents for neutropenic fever, with Hickman-type central venous catheter, who developed mucocutaneous and soft tissue infections with rapidly progressive and devastating course. Cultures from the skin of both patients and from blood of one of them grew S. maltophilia. Both patients died and post mortem examination of the patient with S. maltophilia bacteremia revealed extensive soft tissue necrosis and a vegetation on the mitral valve that grew S. maltophilia. The infection occurred in both patients at the same time and in the same ward. Epidemiological study was done, and surveillance cultures grew the organism from the faucets from the room of 1 patient and also from some of the neighboring rooms in our ward but not from any other ward nor in the water reservoir of the building.

Entities:  

Mesh:

Year:  2002        PMID: 12018671     DOI: 10.1097/00000441-200205000-00008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  15 in total

Review 1.  The role of water in healthcare-associated infections.

Authors:  Brooke K Decker; Tara N Palmore
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

2.  Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient.

Authors:  Young Min Son; So Young Na; Hye Young Lee; Jin Ok Baek; Jong Rok Lee; Joo Young Roh
Journal:  Ann Dermatol       Date:  2009-11-30       Impact factor: 1.444

Review 3.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 4.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

Review 5.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

6.  Stenotrophomonas maltophilia infections: Clinical characteristics in a military trauma population.

Authors:  Shane B Patterson; Katrin Mende; Ping Li; Dan Lu; M Leigh Carson; Clinton K Murray; David R Tribble; Dana M Blyth
Journal:  Diagn Microbiol Infect Dis       Date:  2019-11-23       Impact factor: 2.803

Review 7.  The versatility and adaptation of bacteria from the genus Stenotrophomonas.

Authors:  Robert P Ryan; Sebastien Monchy; Massimiliano Cardinale; Safiyh Taghavi; Lisa Crossman; Matthew B Avison; Gabriele Berg; Daniel van der Lelie; J Maxwell Dow
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

8.  Quality of Drinking Water Treated at Point of Use in Residential Healthcare Facilities for the Elderly.

Authors:  Rossella Sacchetti; Giovanna De Luca; Emilia Guberti; Franca Zanetti
Journal:  Int J Environ Res Public Health       Date:  2015-09-09       Impact factor: 3.390

9.  Computed Tomography Findings of Community-Acquired Stenotrophomonas Maltophilia Pneumonia in an Immunocompetent Patient: A Case Report.

Authors:  Yoon Ki Cha; Jeung Sook Kim; Seong Yeon Park; Jin Young Oh; Jae Hyun Kwon
Journal:  Korean J Radiol       Date:  2016-10-31       Impact factor: 3.500

Review 10.  Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.

Authors:  Anthony A Adegoke; Thor A Stenström; Anthony I Okoh
Journal:  Front Microbiol       Date:  2017-11-30       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.